McKesson Corporation stock upgraded to Buy by Wall Street Zen amid recent pullback

Wall Street Zen has upgraded McKesson Corporation stock (ISIN: US58155Q1031) from Hold to Buy, citing robust financials and growth in healthcare distribution. Despite a recent price dip on NYSE in USD, analysts see undervaluation. DACH investors eye stability in pharmaceuticals supply chain.

McKesson Corporation stock received a significant boost today as Wall Street Zen upgraded its rating from Hold to Buy. This move highlights the company's strong quarterly results, with revenue up 11.4% year-over-year and earnings surpassing expectations. For DACH investors, McKesson offers defensive exposure to U.S. healthcare distribution amid global supply chain tensions.

As of: 22.03.2026

By Dr. Elena Voss, Senior Healthcare Equity Analyst – Tracking U.S. pharmaceutical distributors' resilience in volatile markets, McKesson stands out for its margin discipline and tech-driven efficiencies.

Wall Street Zen's Upgrade Signals Confidence

Wall Street Zen issued the upgrade early today, March 22, 2026, following McKesson's February 4 quarterly report. Analysts pointed to solid revenue growth and strategic expansions in specialty pharmacy and medical-surgical supplies. The firm views these as key drivers for sustained performance in a sector facing regulatory scrutiny.

McKesson, listed on NYSE under ticker MCK with ISIN US58155Q1031, trades in USD. The upgrade counters recent market hesitancy, positioning the stock as attractive for value-oriented portfolios. Institutional interest persists, with recent stake adjustments by funds like Calamos Advisors.

This development matters now because healthcare distribution remains recession-resistant. DACH investors, navigating EU regulatory shifts, find McKesson's U.S.-centric model a hedge against local pharma pricing pressures.

Recent Pullback Creates Buying Opportunity

McKesson stock has faced short-term pressure, declining around 5.9% over the past week and 6.5% in the last month on NYSE in USD. Despite this, year-to-date gains stand at 7.6%, with a robust 34.5% return over the past year. Longer-term, returns exceed 159% over three years.

Valuation models suggest the stock trades at a discount. A DCF analysis estimates intrinsic value near levels implying 40% upside from recent NYSE prices around USD 885. P/E at 25.0x exceeds the healthcare sector average of 21.2x but aligns with peers.

For German-speaking investors, this pullback mirrors broader healthcare sector rotations but underscores McKesson's undervaluation relative to growth prospects. European portfolios increasingly allocate to U.S. healthcare for yield stability.

Financial Strength Underpins the Outlook

McKesson's latest quarter showcased revenue expansion and free cash flow nearing $9.61 billion over trailing twelve months. Investments in technology solutions bolster margins in distribution. The company supplies pharmaceuticals and medical products to providers nationwide.

As a leader in U.S. healthcare logistics, McKesson navigates opioid litigation and reimbursement changes adeptly. Earnings growth supports dividend sustainability, appealing to income-focused DACH investors seeking USD yields above Eurozone peers.

Sector metrics highlight resilience: order backlogs remain steady, pricing power intact amid inflation. Analysts project continued FCF growth through 2029, fueling buybacks and expansions.

Strategic Initiatives Drive Growth

McKesson advances in specialty pharmacy, capturing high-margin segments like oncology drugs. Medical-surgical distribution gains from hospital consolidations. Tech platforms enhance supply chain visibility, reducing costs.

These moves position McKesson ahead of digital transformation in healthcare. Partnerships with providers expand service revenue, diversifying from pure distribution. For DACH investors, this mirrors trends in Europe's centralized health systems but with U.S. scale advantages.

Global footprint, though U.S.-heavy, taps Canadian and international markets. Regulatory tailwinds from biosimilar approvals boost volume.

Risks and Challenges Ahead

Despite positives, McKesson faces drug pricing reforms and litigation risks from past opioid distributions. Supply chain disruptions persist post-pandemic. Competition from AmerisourceBergen and Cardinal Health pressures margins.

Macro factors like interest rates impact hospital spending. Valuation, while attractive, assumes execution on growth initiatives. Investors should monitor Q1 2026 results for confirmation.

DACH portfolios must weigh currency risk; USD strength benefits returns but exposes to Fed policy shifts versus ECB.

Relevance for DACH Investors

German, Austrian, and Swiss investors benefit from McKesson's stability in defensive healthcare. Amid EU pharma regulations like HTA reforms, U.S. distributors offer uncorrelated returns. Dividend yields provide income superior to local bonds.

Portfolio diversification favors MCK for its low beta versus DAX or SMI. Institutional flows from Europe into U.S. healthcare validate this. Currency-hedged ETFs make access straightforward.

Current upgrade timing aligns with year-end reallocations, enhancing appeal for conservative mandates.

Market Positioning and Peers

McKesson trades at premiums to sector but justified by FCF quality. Peers show similar multiples, yet McKesson's execution edges out. Sector tailwinds from aging populations support all.

Watch for M&A activity; bolt-ons could accelerate growth. Analyst consensus leans positive post-upgrade.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.